Liquid Biopsy
News and reporting on cell-free DNA testing.
Biodesix Preliminary Revenues up 39 Percent for Q4, 45 Percent for 2024
The company projected that it grew its revenues by double digits in both diagnostic testing and biopharma and other services.
The NCI-led Vanguard study has selected tests from Guardant Health and ClearNote Health to move forward after a vigorous technology assessment.
Liquid Biopsy Developer Oxford Cancer Analytics Raises $11M
The company, which is based in England and has operations in Canada, is developing a liquid biopsy test for lung cancer detection.
Myriad Genetics, MD Anderson Partner to Study Clinical Utility of MRD Assay
Under the five-year agreement, the partners will assess the clinical utility of Myriad's Precise MRD test in breast, gastrointestinal, genitourinary, and gynecological cancers.
Guardant Health, Cota Partner to Provide Clinicogenomic Cancer Data Resource for Biopharma
The companies believe that creating a unified set of clinical and genomic data will help biopharma clients accelerate their development of new targeted therapies.